Comparative Pharmacology
Head-to-head clinical analysis: DIAZOXIDE versus NORMODYNE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIAZOXIDE versus NORMODYNE.
DIAZOXIDE vs NORMODYNE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diazoxide is a potassium channel activator that opens ATP-sensitive potassium channels in pancreatic beta cells, inhibiting insulin secretion. It also causes peripheral vasodilation by activating potassium channels in vascular smooth muscle.
Competitive antagonist at beta-1 adrenergic receptors with additional alpha-1 adrenergic receptor blocking activity, resulting in vasodilation and decreased heart rate, contractility, and cardiac output.
Hypertension: 1-3 mg/kg IV bolus, up to 150 mg, repeated every 5-15 minutes to achieve desired blood pressure. Hyperinsulinemic hypoglycemia: 3-8 mg/kg/day PO divided every 8-12 hours.
Oral: Initial 100 mg twice daily, increase by 100 mg/day every 2 weeks; maintenance 200-400 mg twice daily. Max 1200 mg/day. IV: 20 mg (1 mL) over 2 minutes, repeat if needed at 10 min intervals up to total 300 mg.
None Documented
None Documented
Clinical Note
moderateDiazoxide + Torasemide
"Diazoxide may increase the hypotensive activities of Torasemide."
Clinical Note
moderateDiazoxide + Travoprost
"Diazoxide may increase the hypotensive activities of Travoprost."
Clinical Note
moderateDiazoxide + Unoprostone
"Diazoxide may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateDiazoxide + Epoprostenol
"Diazoxide may increase the hypotensive activities of Epoprostenol."
Terminal half-life: 20-36 hours (adults), 9-24 hours (children). Context: shorter after IV bolus due to redistribution; prolonged in renal impairment.
8-12 hours; extended in hepatic impairment (up to 20 hours) and renal impairment (up to 15 hours)
Renal: ~50% unchanged; minor biliary/fecal excretion.
Renal: 55-65% as unchanged drug and metabolites; Fecal: ~20% via bile; Hepatic metabolism: ~25%
Category C
Category C
Antihypertensive Agent
Antihypertensive Agent